Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

ABSTRACT: This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity. The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator’s existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.

DISEASE(S): Solid Tumour,Selected Solid Tumours; - Cutaneous Melanoma - Pancreatic Ductal Adenocarcinoma- Ovarian Cancer- Colorectal Adenocarcinoma- Hepatocellular Carcinoma- Gallbladder Cancer And Cholangiocarcinoma- Uveal Melanoma- Gastric Adenocarcinoma (including Ge Junction)- Estrogen Receptor Positive Breast Cancer- Anaplastic Thyroid Cancer,Selected Solid Tumours; - Cutaneous Melanoma - Pancreatic Ductal Adenocarcinoma- Ovarian Cancer- Colorectal Adenocarcinoma- Hepatocellular Carcinoma- Gallbladder Cancer And Cholangiocarcinoma...,Cancer

PROVIDER: 2288968 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression

Project description:Cholangiocarcinoma is a cancer of the hepatic bile ducts that is typically detected at a stage too advanced for resection. Additionally, chemotherapy is of limited efficacy, hence, novel therapeutic approaches are urgently required, including targeting of the cancer stroma. A macrophage-derived signal, tumour necrosis factor-like weak inducer of apoptosis (TWEAK), binds to cell-surface fibroblast growth factor-inducible 14 (Fn14), on cholangiocarcinoma cells to induce cytokine and chemokine expression and secretion. These TWEAK-inducible factors from cholangiocarcinoma cells can also affect macrophage polarisation. We characterised proteins secreted by four well-characterised human cholangiocarcinoma cell lines in the presence or absence of recombinant human TWEAK (100 ng/ml), to discover novel TWEAK-inducible factors that could drive pro-tumour niche formation.

| MSV000084273 | MassIVE

Transcriptional repression and apoptosis influence the effect of APOBEC3A/3B functional polymorphisms on biliary tract cancer risk

Project description:APOBEC3s-related somatic mutations are the predominant burden in biliary tract cancers (BTCs). Here, we reveal the effects and mechanisms of APOBEC3A/3B functional polymorphisms on cholangiocarcinoma and gallbladder cancer (GBC). rs2267401-G at the APOBEC3B promoter decreases cholangiocarcinoma risk but increased GBC risk. rs2267401-G confers a decreased APOBEC3B promoter activity in cholangiocarcinoma cells but an increased activity in GBC cells. rs12157810-C at the APOBEC3A promoter decreases the risk of BTCs. rs12157810-C up-regulated the promoter activity in both cells. APOBEC3A overexpression attenuates cancer evolution via causing apoptosis, in contrast to APOBEC3B. Inflammatory factors promote cancer evolution via interacting with transcriptional repressors regulating the APOBEC3A/3B promoters. ATAC-seq was used to identify the difference between transcriptional networks of cholangiocarcinoma and GBC.

2022-01-07 | GSE166372 | GEO

2-arachidonoyl glycerol (2-AG) modulated miRNAs expression in human cholangiocarcinoma

Project description:The endocannabinoid system (ECS) is dysregulated in various liver diseases. Biliary tract cancers (BTCs) encompass gallbladder carcinoma, intrahepatic, perihilar and distal cholangiocarcinoma. Previously we have shown that the two major endocannabinoids (ECs), anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) exerted opposing effects on BTCs cell lines in which 2-AG promoted tumor proliferation. The underlying mechanism and regulation of 2-AG on miRNAs expression in BTCs remain inconclusive.

2022-05-01 | GSE188863 | GEO

Proteomics of thyroid tumours - Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy

Project description:Although most thyroid tumours are benign, thyroid cancer represents the most common malignancy of the endocrine system, comprising mainly follicular and papillary thyroid carcinomas (FTC and PTC, respectively). Previous studies have shed some light on the molecular pathogenesis of thyroid cancer but there have not been any comprehensive mass spectrometry-based proteomic studies to reveal protein expression differences between thyroid tumours and the molecular alterations associated with tumour malignancy. We applied a label-free quantitative mass spectrometry analysis to compare normal thyroid tissue with the three most common tumours of the thyroid gland: follicular adenoma, follicular carcinoma and papillary carcinoma.

2017-05-03 | PXD002732 | Pride

Effect of 14 hours of starvation on gene expression in the WM983B cell line using RNA-seq / Effect of HA15 resistance on gene expression in the WM983B cell line using RNA-seq

Project description:In order to examine the effect of starvation on gene expression and its contribution to the elevated ER stress, autophagy and apoptotic mechanisms we performed RNA-seq experiment on starved melanoma cells and on cells growing under normal cell conditions.The highest expression difference were seen for the RP11-134F2.8 gene (217 fold change) and the RP11-618G20.1 gene (64 fold change). Two starvation related genes including the SLCO4C1 (32 fold change), and PIK3IP1 (14 fold change) genes were also highly expressed in the starved WM983B cell population. We are the first who successfully established HA15 resistant melanoma cell lines (WM983BHA15RES) against 30uM HA15. In order to define gene expression alterations associated with the HA15 resistant phenotype we performed RNAseq analysis on the newly developed resistant melanoma cell line and compared the gene expression signature to the original WM983 cell line.

2021-03-02 | GSE164261 | GEO

A pan-cancer study to identify and characterize synthetic lethal drugs in BAP1-deficient cancers

Project description:BRCA-1 Associated Protein (BAP1) is a deubiquitinating enzyme that acts as a tumour suppressor. Inactivating mutations in the BAP1 gene have been identified in many cancers including cholangiocarcinoma, hepatocellular carcinoma, mesothelioma, uveal melanoma and renal cell carcinoma. Current standard therapeutic approaches for BAP1-deficient tumours are not particularly promising, contributing to poor overall survival and disease-free survival rates. Here, we found BAP1 to mediate the turnover of the key proteins in the DNA nucleotide excision repair (NER) pathway, and therefore promotes DNA repair. Importantly, we demonstrate that the loss of functional BAP1 sensitise tumour cells to LSD1 inhibitor, SP2509, in vitro and in vivo, through further impairment of NER efficiency. When used in combination with PARP1 inhibitor, Olaparib, we show that a synergistic drug combination response is achieved. Overall, our study identifies a drug combination approach that has the potential to be exploited clinically to target BAP1 deficient tumours.

2022-09-15 | PXD028470 | JPOST Repository

Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer

Project description:Poor prognosis in gallbladder cancer is due to late presentation of the disease, lack of reliable biomarkers for early diagnosis and limited targeted therapies. Early diagnostic markers and novel therapeutic targets can significantly improve clinical management of GBC. We carried out quantitative proteomic analysis using a panel of gallbladder cancer cell lines using isobaric tags for relative and absolute quantitation (iTRAQ). We identified 3,655 proteins among which 654 were found to be overexpressed and 387 were downregulated in the invasive cell lines (OCUG-1, NOZ and GB-d1) compared to the non-invasive cell line, TGBC24TKB. Among these, macrophage inhibitory factor (MIF) was observed to be >3-fold overexpressed. MIF is a pleiotropic proinflammatory cytokine that plays a causative role in multiple diseases including cancer. MIF has been reported to play a central role in tumor cell proliferation and invasion in several cancers. Immunohistochemical staining confirmed our findings showing overexpression of MIF in 21 of 29 gallbladder adenocarcinoma cases. A significant decrease in cell viability, colony forming ability and invasive property of the gallbladder cancer cells was observed upon MIF inhibition using MIF siRNA and MIF antagonists. Our findings support the role of MIF in tumor aggressiveness and suggest its potential application as a therapeutic target for gallbladder cancer.

2015-10-02 | PXD001566 | Pride

Cell survival and adaptation to chronic endoplasmic reticulum stress in thyrocytes

Project description:The large secretory glycoprotein, thyroglobulin, is the primary translation product of thyroid follicular cells. This difficult-to-fold protein is readily susceptible to structural alterations that render the misfolded thyroglobulin unable to be exported from the endoplasmic reticulum (ER) a known cause of congenital hypothyroidism, with severe, chronic thyrocyte ER stress. Nevertheless, patients with this disease commonly grow a goiter indicative of thyroid cell survival and adaptation. To model this, we have treated PCCl3 thyrocytes with continuous exposure to tunicamcyin (causing an ER stress that can be specifically attributed to thyroglobulin misfolding). In response, PCCl3 cells escape by downregulating expression of Mfsd2a (the tunicamycin transporter). By contrast, following CRISPR/Cas9-mediated deletion of Mfsd2a, PCCl3 cells cannot escape the continuous, chronic effects of high-dose tunicamycin (as demonstrated by persistent accumulation of unglycosylated thyroglobulin); nevertheless the thyrocytes live and grow. A comprehensive proteomic analysis of these cells adapted to chronic ER protein misfolding reveals many hundreds of up-regulated proteins, supporting stimulation of ER chaperones, oxidoreductases, and stress responses as well as lipid biosynthesis pathways. Further, we noted: a) increased phospho-AMP-kinase-B (suggesting upregulated AMPK activity) and decreased phospho-S6 and protein translation (suggesting decreased mTOR activity), consistent with conserved cell survival/adaptation pathways; and b) a suggestion of less differentiated thyrocyte phenotype with decreased PAX8, FOXE1, and TPO protein, as well as a significant decrease of thyroglobulin mRNA levels.

2020-02-25 | MSV000085006 | MassIVE

Transcriptomic analysis of tumour-associated macrophages in wildtype and Colec11-/- mice

Project description:Collectin-11 (CL-11) is a recently described soluble C-type lectin, which has distinct roles in embryonic development, host defence, autoimmunity and fibrosis. Here we show that CL-11 also plays an important role in promoting melanoma growth. Colec11 deficient mice engrafted with B16 melanoma cells displayed significantly reduced tumour burden compared with WT mice. Cellular and molecular analyses showed that melanoma tumour in Colec11-/- mice had: i) lower levels of angiogenesis and tumour cell proliferation, ii) less immunosuppressive tumour microenvironment characterised by high lymphocyte to myeloid infiltrate ratio, increased infiltration of CD8+ T cells into the tumour core, high levels of anti-tumour cytokines/chemokines, reprogramming macrophages to M1 phenotype.

2023-05-02 | GSE193454 | GEO

RNA-sequencing for dynamic epi-transcriptomic landscape mapping with disease progression in ER-positive breast cancer

Project description:Advanced breast cancer is characterised by enhanced tumour adaptability to therapeutic pressure and the metastatic microenvironment. Transcriptome differences in three ER positive (ER+) cell models are uncovered through this RNA-seq analysis of MCF7 (endocrine sensitive), LY2 (endocrine resistant) and T347 (derived from an ER-positive, treatment resistant brain metastatic patient tumour) cells.

2023-05-16 | GSE176534 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data